domvanalimab + quemliclustat + zimberelimab + platinum-based doublet

This is an investigative **combination regimen** of four agents: - **Domvanalimab** (a monoclonal antibody targeting TIGIT, an immune checkpoint) - **Quemliclustat** (also known as AB680, a small molecule inhibitor of CD73, thereby blocking adenosine production in the tumor microenvironment) - **Zimberelimab** (a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1, PD-1) - **Platinum-based doublet chemotherapy** (combination of a platinum compound, such as cisplatin or carboplatin, with a third-generation chemotherapeutic agent—commonly gemcitabine, paclitaxel, docetaxel, vinorelbine, irinotecan, or pemetrexed, used as standard first-line chemotherapy for various cancers including pancreatic and lung cancer[2][4][5]) This combination is under investigation in metastatic and locally advanced pancreatic cancer and may be under consideration for other solid tumors. The rationale is to overcome immunosuppression in the tumor microenvironment via combined checkpoint blockade and adenosine pathway inhibition, alongside cytotoxic chemotherapy to maximize cancer cell kill[3][5]. Arcus Biosciences is the primary developer of domvanalimab, quemliclustat, and zimberelimab.